Prosecution Insights
Last updated: November 04, 2026
Application No. 18/607,474

MULTILAYERED CAPSULE WITH CONTROLLABLE ARRANGEMENT OF LAYERS AND INDUSTRIAL SYSTEMS AND PROCESSES OF FABRICATING THE SAME

Final Rejection §102§112
Filed
Mar 17, 2024
Priority
Mar 19, 2023 — IL 301481
Examiner
MERCIER, MELISSA S
Art Unit
1615
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Capsule Minimal Ltd.
OA Round
2 (Final)
72%
Grant Probability
Favorable
3-4
OA Rounds
2m
Est. Remaining
78%
With Interview

Examiner Intelligence

Grants 72% — above average
72%
Career Allowance Rate
878 granted / 1217 resolved
+12.1% vs TC avg
Moderate +6% lift
Without
With
+5.7%
Interview Lift
resolved cases with interview
Typical timeline
2y 10m
Avg Prosecution
41 currently pending
Career history
1265
Total Applications
across all art units

Statute-Specific Performance

§101
2.1%
-37.9% vs TC avg
§103
43.9%
+3.9% vs TC avg
§102
14.8%
-25.2% vs TC avg
§112
23.4%
-16.6% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1217 resolved cases

Office Action

§102 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Status of Application Receipt of Applicant’s remarks, amended claims, and amended specification filed on September 28, 2026 is acknowledged. Claims 21-37 are pending in this application. Claims 1-20 have been cancelled. Claims 21-29 have been amended. All pending claims are under examination in this application. Withdrawn Objections/Rejections Specification The objection to the title of the invention as non-descriptive has been withdrawn in view of the amendment to the title to recite “Dissolvable Solid Complex with Sequentially Arranged Compacted Particulate Layers”. Claim Rejections - 35 USC § 112 The rejection of claims 21-37 under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement has been withdrawn in view of the amendment to delete “a solid body” from the claim. The rejection of claims 27-29 under 35 U.S.C. 112(d) or pre-AIA 35 U.S.C. 112, 4th paragraph, as being of improper dependent form for failing to further limit the subject matter of the claim upon which it depends, or for failing to include all the limitations of the claim upon which it depends because claim 27 recites “wherein the solid body is one pellet of a plurality of pellets”, however, claim 21 from which it depends recites “a dissolvable solid complex” has been withdrawn in view of the amendment to the claim to recite “the dissolvable solid complex of claim 21, the sequence of soluble layers forms a first pellet, and wherein the solid complex further comprises a second pellet formed by a further sequence of soluble layers, each soluble layer of the further sequence comprising compacted solid particles, wherein each layer of the further sequence other than an outermost layer of the further sequence is at least partially covered by and in contact with an adjacent outward layer of the further sequence”. Claim Rejections - 35 USC § 102 The rejection of claims 21-26 and 30-37 under 35 U.S.C. 102(a)(1) as being anticipated by Digenis et al. (US 5,672,359) has been withdrawn in view of the arguments regarding the different architecture of the capsule versus amended claim 21 which requires a sequence of soluble layers, each soluble layer comprising compacted solid particles, in which each layer other than an outermost layer is at least partially covered by and in contact with an adjacent outward layer of the sequence, the first and second payload compositions occupying respective layers of that sequence. Newly Applied Rejections Claim Objections Claims 23-24, 26, 29, 32-35, and 37 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. The closest prior art is that of Ludwig, described below. There is no motivation or teachings within the art to modify those teachings to arrive at the instant claims. Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claims 21-22, 35, 27-28, 30-31 and 36 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Ludwig et al. (US 2005/0118306). Ludwig discloses composite particles that impart unique, entertaining optical and/or organoleptic effects in food products when exposed to an aqueous environment. In one embodiment, the composite particles have a least two layers which, when exposed to an aqueous environment, provide at least two sequential changes in the food product. Such changes can include changes in color or other visual appearance characteristics, flavor, and the like, as well as combinations thereof. In another embodiment, the composite particles are included in a powdered beverage mix wherein the powdered beverage mix itself provide the initial sequential change followed, by an appropriate delay, the second sequential change; further sequential changes can be provided, if desired, by providing additional layers with the appropriate optical and/or organoleptic ingredients therein (abstract). The composite particles comprise cores and/or coating layers that are edible, water-soluble materials (e.g., carbohydrates, gels, proteins, lipids, and the like) (paragraph 0020). The coating is formed or deposited on the exterior surfaces of the core particles of the composite particles in a manner in which it encapsulates the surface of the core particles. "Encapsulation" or equivalent language means the coating formed on the core particle covers essentially all of the outer surface of a particle (paragraph 0021). The Examiner has interpreted carbohydrates, gels, proteins, lipids, and the like to be the payload substance. Optional ingredients can include caffeine, vitamins, minerals and/or nutraceuticals (paragraph 0049). Figure 1B discloses a particle with a first layer and a second layer on a core particle. Regarding claim 22, Figure 1B discloses the layers on top of one another (adjacent). Regarding claim 25 and 27, as noted above, additional layers can be added. Regarding claim 28, the sequential effect can be provided with two or more different composite particles (paragraph 0051). Regarding claim 30, as noted above, the layers provide an optical and/or organoleptic properties. Regarding claim 31, it may be desirable to delay the onset and/or extend the length of the optical and/or organoleptic effects. The optical and/or organoleptic effects (i.e., when they begin and how long they last) can be controlled by manipulating the composition and thickness of the coating and the concentration of the optical and/or organoleptic producing ingredients within the various layers (paragraph 0031). Regarding claim 36, the composite particles can contain 1-60% gum Arabic, gelatin, or other slow dissolving food polymers (paragraph 0040). It is the position of the Examiner that the food polymer would increase the viscosity of the composition. Ludwig, therefore, anticipates the rejected claims. Conclusion The prior art made of record and not relied upon is considered pertinent to applicant's disclosure: Pather et al. (WO03005944) discloses sequential drug delivery systems for the administration route that includes delivering the active ingredient to a desired site in a body of the mammal, and, sequentially, at the desired site, promoting dissolution and absorption of the active ingredient. In a preferred embodiment, the pH of the localized environment of the active ingredient is sequentially modified to promote dissolution and absorption (abstract). However, a multilayered tablet is disclosed and not a coated particulate wherein the coating layer comprises a payload to be dissolved. Applicants’ amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to MELISSA S MERCIER whose telephone number is (571)272-9039. The examiner can normally be reached M-F 6:30 am to 4 pm EST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Robert A Wax can be reached at 571-272-0623. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /MELISSA S MERCIER/Primary Examiner, Art Unit 1615
Read full office action

Prosecution Timeline

Mar 17, 2024
Application Filed
Jul 02, 2026
Non-Final Rejection mailed — §102, §112
Sep 22, 2026
Examiner Interview Summary
Sep 28, 2026
Response Filed
Oct 28, 2026
Final Rejection mailed — §102, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12778918
PARENTERAL NUTRITION FORMULATION
3y 6m to grant Granted Nov 03, 2026
Patent 12778886
Oral Hydrogel Compositions and Uses
3y 6m to grant Granted Nov 03, 2026
Patent 12779034
SELF-SUSTAINED RELEASE IMMUNE ADJUVANT SUSPENSION, PREPARATION METHOD THEREFOR, AND USE THEREOF
3y 4m to grant Granted Nov 03, 2026
Patent 12779152
DRY POWDER FORMULATIONS OF EPINEPHRINE AND ASSOCIATED METHODS
2y 9m to grant Granted Nov 03, 2026
Patent 12773416
COMPOSITION, ARTICLE AND METHOD FOR AFFECTING A MAMMAL
4y 0m to grant Granted Oct 27, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
72%
Grant Probability
78%
With Interview (+5.7%)
2y 10m (~2m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 1217 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month